Flow Cytometry of Hematological Malignancies - Claudio Ortolani

Flow Cytometry of Hematological Malignancies

Buch | Hardcover
464 Seiten
2021 | 2. Auflage
Wiley-Blackwell (Verlag)
978-1-119-61125-7 (ISBN)
202,18 inkl. MwSt
Flow cytometric analysis is often integral to the swift and accurate diagnosis of leukemias and lymphomas of the blood, bone marrow, and lymph nodes. However, in the fast-moving and expanding field of clinical hematology, in can be challenging to remain up to speed with the latest biological research and technological innovations. »Flow Cytometry of Hematological Malignancies« has been designed to provide all those working in hematological oncology with a practical, cutting-edge handbook, featuring clear and fully illustrated guidance on all aspects of cytometry's role in diagnosis and analysis.

This essential second edition includes:
  • Explorations of more than 70 antigens
  • Full-color illustrations throughout
  • New descriptions of recently discovered markers
  • WHO classifications of hematological neoplastic diseases
  • Helpful tips for result interpretation and analysis

Featuring all this and more, »Flow Cytometry of Hematological Malignancies«, Second Edition, is an invaluable resource for both trainee and experienced hematologists, hematopathologists, oncologists, and pathologists, as well as medical students and diagnostic lab technicians.

Dr Claudio Ortolani, is an expert in the area of diagnosis of hematological malignancies. Now retired, Dr Ortolani was Consultant in the Department of Clinical Pathology at Venice General Hospital, Venice, Italy. He is one of the founding members of the Italian Society for Cytometric Cell Analysis (ISCCA), of whose board he is currently a member. He has taught and lectured internationally on how to use flow cytometry to aid in diagnosing hematological diseases.

Foreword to the First Edition by Maryalice Stetler-Stevenson


Foreword to the First Edition by Bruno Brando


Foreword to the Second Edition by Michael J Borowitz


Preface to the First Edition


Preface to the Second Edition


1 ANTIGENS


Clustered (CD) Antigens


CD1 Antigens, XX


CD2 Antigen, XX


CD3 Antigen, XX


CD4 Antigen, XX


CD5 Antigen, XX


CD7 Antigen, XX


CD8 Antigen, XX


CD10 Antigen, XX


CD11b Antigen, XX


CD11c Antigen, XX


CD13 Antigen, XX


CD14 Antigen, XX


CD15 Antigen, XX


CD16 Antigen, XX


CD19 Antigen, XX


CD20 Antigen, XX


CD22 Antigen, XX


CD23 Antigen, XX


CD24 Antigen, XX


CD25 Antigen, XX


CD26 Antigen, XX


CD27 Antigen, XX


CD28 Antigen, XX


CD30 Antigen, XX


CD33 Antigen, XX


CD34 Antigen, XX


CD38 Antigen, XX


CD43 Antigen, XX


CD45 Antigen, XX


CD45 Isoforms, XX


CD48 Antigen, see SLAM molecules, XX


CD49 Antigens, XX


CD56 Antigen, XX


CD57 Antigen, XX


CD61 Antigen, XX


CD62L Antigen, XX


CD64 Antigen, XX


CD65 Antigen, XX


CD66c Antigen, XX


CD71 Antigen, XX


CD79 Antigen, XX


CD81 Antigen, XX


CD84 Antigen, see SLAM molecules, XX


CD103 Antigen, XX


CD123 Antigen, XX


CD117 Antigen, XX


CD138 Antigen, XX


CD150 Antigen, see SLAM molecules, XX


CD158 Antigen, see KIRs, XX


CD181-186, 191-199 Antigens, see Chemokines and Chemokine Receptors, XX


CD200 Antigen, XX


CD229 Antigen, see SLAM molecules, XX


CD244 Antigen, see SLAM molecules, XX


CD280-290 Antigens, see Toll-like Receptors, XX


CD305 Antigen, XX


CD307 (IRTA) Antigen Family, XX


CD319 Antigen, see SLAM molecules, XX


CD352-353 Antigens, see SLAM molecules, XX


CD371 Antigen, XX


Non clustered (or primarily known with other names) antigens


Bcl-2 Protein, XX


Chemokines and Chemokine Receptors, XX


CRLF2, XX


Cytotoxic Proteins, XX


HLA-DR Antigen, XX


Immunoglobulins, XX


KIR, CD158 Isoforms, XX


Myeloperoxidase (MPO), XX


NG2 Antigen, XX


PCA-1 Antigen, XX


ROR-1 Antigen, XX


SLAM Molecules and SLAM Associated Protein (SAP), XX


SOX11, XX


T-cell Receptor (TCR), XX


Terminal Deoxy-nucleotidyl Transferase (TdT), XX


Toll-like Receptors (TLR), XX


VS38 Antigen, XX


ZAP-70 Protein, XX





2 DISEASES


Myeloproliferative neoplasms, XXX


Chronic myeloid leukemia (CML), XXX


Myeloproliferative neoplasms other than CML, XXX


Chronic neutrophilic leukemia (CNL), XXX


Polycythemia vera (PV), XXX


Primary myelofibrosis (PMF), XXX


Essential thrombocythemia (ET), XXX


Chronic eosinophilic leukemia (CEL), XXX


Mastocytosis, XXX


Acute masT-cell leukemia (AMCL), XXX


Chronic masT-cell leukemia (CMCL), XXX


Myelomastocytic leukemia (MML), XXX


Myelodysplastic/myeloproliferative neoplasms, XXX


Chronic myelomonocytic leukemia (CMML), XXX


Other myelodysplastic/myeloproliferative neoplasms and related conditions, XXX


Juvenile myelomonocytic leukemia (JMML), XXX


Atypical CML bcr/abl negative (ACML), XXX


RAS-associated autoimmune leukoproliferative disorder (RALD), XXX


Myelodysplastic syndromes, XXX


Myeloid neoplasms with germline predisposition, XXX


Acute myeloid leukemias, XXX


AMLs with recurrent genetic anomalies, XXX


AMLs with chromosomal anomalies, XXX


AMLs with gene mutations, XXX


AMLs with recurrent genetic anomalies, not recognized by the WHO


classification, XXX


AMLs with myelodysplastic related changes (AML-MRC), XXX


AMLs not otherwise specified, XXX


AML with minimal differentiation, XXX


AML without maturation, XXX


AML with maturation, XXX


Acute myelomonocytic leukemia (AMMoL), XXX


Acute monoblastic or monocytic leukemia (AMoL), XXX


Pure erythroid leukemia (PEL), XXX


Acute megakaryoblastic leukemia (AMKL), XXX


Acute basophilic leukemia (ABL), XXX


Myeloid proliferations associated with Down syndrome, XXX


Transient abnormal myelopoiesis (TAM), XXX


AMLs in patients with Down syndrome, XXX


Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL), XXX


Acute leukemias with ambiguous lineage attribution (ALAL), XXX


Acute undifferentiated leukemias (AUL), XXX


Mixed phenotype acute leukemias (MPAL), XXX


Neoplastic diseases of B and T lymphatic precursors, XXX


B lymphoblastic leukemia/lymphoma,


not otherwise specified (B-ALL/LBLnos), XXX


B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies, XXX


T lymphoblastic leukemia/lymphoma (T-ALL/LBL), XXX


Early T-cell precursors lymphoblastic leukemia (ETP-ALL), XXX


NK lymphoblastic leukemia/lymphoma (NK-ALL/LBL), XXX


Neoplastic diseases of mature B cells, XXX


Chronic lymphocytic leukemia/small


lymphocytic lymphoma (B-CLL/SLL), XXX


Familial B-CLL, XXX


Richter syndrome, XXX


Monoclonal B-cell lymphocytosis (MBL), XXX


B-cell prolymphocytic leukemia (B-PLL), XXX


Lymphoplasmacytic lymphoma (LPL), XXX


Heavy chain disease (HCD), XXX


Gamma heavy chain disease, XXX


Mu heavy chain disease, XXX


Alpha heavy chain disease, XXX


Hairy cell leukemia (HCL), XXX


Hairy cell leukemia, variant (HCL-v), XXX


Hairy cell leukemia, Japanese variant (HCL-J), XXX


Splenic diffuse red pulp lymphoma (SDRPL), XXX


Marginal zone lymphomas (MZL), XXX


Nodal marginal zone lymphoma (NMZL), XXX


Splenic marginal zone lymphoma (SMZL), XXX


Extranodal marginal zone lymphoma (EMZL/MALToma), XXX


Clonal B-cell lymphocytosis with MZL-like phenotype (CBL-MZ), XXX


Follicular lymphoma (FCL), XXX


Testicular follicular lymphoma, XXX


Duodenal type follicular lymphoma, XXX


Pediatric type follicular lymphoma, XXX


Primitive cutaneous follicular lymphoma (PCFL), XXX


Large B-cell lymphoma with IRF4 rearrangement, XXX


Mantle cell lymphoma (MCL), XXX


Blastic mantle cell lymphoma (BMCL), XXX


Leukemic non nodal mantle cell lymphoma, XXX


Diffuse large B-cell lymphomas (DLBCLs), XXX


DLBCL not otherwise specified (DLBCL nos), XXX


T-cell/histiocyte-rich B-cell lymphoma (THRLBCL), XXX


Primary DLBCL of the CNS (PCNSL), XXX


Primary cutaneous DLBCL, "leg type", XXX


EBV(+) DLBCL nos, XXX


DLBCL associated with chronic inflammation (PAL), XXX


Lymphomatoid granulomatosis (LyG), XXX


Primary mediastinal B-cell lymphoma (PMBCL), XXX


Intravascular large B-cell lymphoma (IVBCL), XXX


ALK-positive large cell lymphoma (ALK(+) LBCL), XXX


Plasmablastic lymphoma (PBL), XXX


Primary effusion lymphoma (PEL), XXX


HHV8-associated lymphoproliferative disorders, XXX


Burkitt lymphoma (BL), XXX


Burkitt leukemia with immature phenotype, XXX


Burkitt-like lymphoma with 11q aberrations, XXX


High grade B-cell lymphoma (HGBL), XXX


Plasma cell neoplasms, XXX


Monoclonal gammopathies of undetermined significance (MGUS), XXX


Multiple myeloma (MM), XXX


Plasma cell leukemia (PCL), XXX


Neoplastic diseases of mature T and NK cells, XXX


T-cell prolymphocytic leukemia (T-PLL), XXX


T-cell large granular lymphocytic leukemia (T-LGL), XXX


Chronic lymphoproliferative disorders of NK cells (CLPD-NK/CNKL), XXX


Aggressive NK-cell leukemia (ANKL), XXX


Adult T-cell leukemia/lymphoma (ATLL), XXX


Extranodal NK/T-cell lymphoma, "nasal type" (ENKTL), XXX


Intestinal T-cell lymphoma (ITCL), XXX


Enteropathy-associated T-cell lymphoma (EATCL), XXX


Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), XXX


Indolent gastro-intestinal T lymphoproliferative disorder, XXX


Hepatosplenic T-cell lymphoma (HTSCL), XXX


Subcutaneous panniculitis-like T-cell lymphoma (SPTCL), XXX


Mycosis fungoides (MF), XXX


Sezary syndrome (SS), XXX


Primary cutaneous CD30(+) lymphoproliferative disorders, XXX


Lymphomatoid papulosis (LyP), XXX


Primary cutaneous anaplastic T-cell lymphoma (cALCL), XXX


Primary cutaneous peripheral T-cell lymphoma (PTCL), XXX


Primary cutaneous TCR (+) T-cell lymphoma (PCGD-TCL), XXX


Primary cutaneous CD8(+) aggressive epidermotropic


cytotoxic T-cell lymphoma, XXX


Primary cutaneous acral CD8(+) T-cell lymphoma


Primary cutaneous lymphoma of the medium/small CD4(+) T cells


(PCSM-TCL), XXX


Peripheral T-cell lymphoma, not otherwise specified (PTCLnos), XXX


Nodal lymphomas of follicular T-helper derivation, XXX


Angioimmunoblastic T-cell lymphoma (AITL), XXX


Follicular T-cell lymphoma (FTCL), XXX


Nodal PTCL with follicular T-helper phenotype, XXX


Anaplastic large cell lymphoma ALK(+) (ALK(+) ALCL), XXX


Anaplastic large cell lymphoma ALK(-) (ALK(-) ALCL), XXX


Breast implant-associated anaplastic large cell lymphoma (biaALCL), XXX


Neoplastic diseases of histiocytic and dendritic cells, XXX


Histiocytic sarcoma (HS), XXX


Langerhans cell histiocytosis (LCH), XXX


Indeterminate dendritic cell tumor (IDCT), XXX


Interdigitating dendritic cell sarcoma (IDCS), XXX


Follicular dendritic cell sarcoma (FDCS), XXX


Erdheim-Chester disease (EDC), XXX


3 APPENDIX


Acute leukemias not recognized by the 2016 WHO classification, XXX


Acute leukemia of myeloid/NK precursors (M/NK-AL), XXX


Acute leukemia of myeloid dendritic cells (MDCL), XXX


Acute leukemia of Langerhans cells, XXX


Mature B-cell lymphoblastic leukemia, XXX


Composite lymphomas, XXX


Hypereosinophilic syndrome (HES), lymphocyte variant, XXX


Indolent T lymphoblastic proliferations (iT-LBP), XXX


Polyclonal lymphocytoses of B lymphocytes, XXX


Persistent polyclonal B-cell lymphocytosis (PPBL), XXX


Persistent polyclonal CD5(+) B-cell lymphocytosis, XXX


Persistent polyclonal B-cell lymphocytosis, Japanese (hairy) variant, XXX


Polyclonal plasmacytoses, XXX


Small round (blue) cell tumors (SR(B)CT), XXX


Index

Erscheinungsdatum
Verlagsort Hoboken
Sprache englisch
Maße 216 x 281 mm
Gewicht 1486 g
Einbandart gebunden
Themenwelt Medizin / Pharmazie Gesundheitsfachberufe MTA - Labor
Medizinische Fachgebiete Innere Medizin Hämatologie
Medizin / Pharmazie Medizinische Fachgebiete Laboratoriumsmedizin
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Studium 2. Studienabschnitt (Klinik) Klinische Chemie / Labordiagnostik
Naturwissenschaften Chemie
ISBN-10 1-119-61125-3 / 1119611253
ISBN-13 978-1-119-61125-7 / 9781119611257
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Hämatologie und Internistische Onkologie

von Dietmar P. Berger; Monika Engelhardt; Justus Duyster

Buch | Softcover (2023)
ecomed-Storck GmbH (Verlag)
129,99